Ipamorelin

Ipamorelin is a selective five-residue peptide that activates ghrelin receptors and elicits strong growth hormone release. Cortisol and prolactin change little relative to other GHRPs, contributing to its selective, generally well-tolerated profile. Combination with CJC-1295 aims to amplify GH pulses and maintain higher IGF-1. Compounded preparations are available by prescription.

• Growth Hormone Support

  Most effective

  Pituitary signaling is linked to increased release of endogenous growth hormone.

• Body Composition

  Effective

  Potential changes include more lean tissue and a lower proportion of body fat.

• Recovery & Repair

  Effective

  Investigations address tissue restoration and recovery following injury or exercise.

• Sleep Quality

  Moderate

  Some experimental schedules are associated with deeper slow-wave sleep and more restorative rest.

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

• Insulin / IGF-1

  Monitor

• Corticosteroids

  Caution

• Thyroid Hormones

  Monitor

• BPC-157

  Compatible

• TB-500

  Compatible

• Ipamorelin + CJC-1295

  Compatible

  The combination aims for synergistic GH responses; this compatibility category does not establish interaction safety.

• Somatostatin Analogs

  Avoid

Diluent: Use bacteriostatic water only; avoid saline because precipitation can occur.

1. Let the refrigerated vial warm to room temperature for 15–20 minutes before preparing it.
2. Disinfect the stopper using an alcohol swab, then wait until the surface has dried fully in the air.
3. Use a sterile syringe to measure your calculated amount of bacteriostatic water. Use this diluent only; avoid saline because precipitation may occur.
4. Introduce the water gradually against the inner glass wall. Keep the stream away from the peptide powder itself.
5. Rotate the vial gently to mix its contents. Do not shake forcefully, because vigorous agitation can degrade the peptide.
6. Wait 2–3 minutes for the powder to dissolve completely. Check that the liquid is transparent and has no color.
7. Measure your calculated dose with an insulin syringe in preparation for administration beneath the skin.
8. Use the abdomen, thigh or upper arm for subcutaneous administration. Change the injection location each time to help prevent lipodystrophy.
9. Return the mixed vial to refrigeration at 2–8°C. Use the prepared solution within 28 days of mixing.

Week 1–2

Sleep may start improving, with mild fluid retention possible during the early period.

Week 2–4

Sleep may deepen and recovery improve; a slight rise in appetite is also possible.

Week 4–8

Changes in energy, the balance of fat and lean tissue, and speed of recovery may become noticeable.

Week 8–12

Visible changes may include better skin quality, less body fat and more lean tissue.

Week 12+

Improvements in strength, body composition and general vitality may persist. These are proposed research timelines rather than established individual outcomes.

• Fluid retention and mild abdominal bloating, particularly at the beginning
• Greater appetite, particularly with members of the GHRP class
• Warmth or flushing around the injection location
• Numbness or tingling, with carpal tunnel-like effects at larger doses
• Lethargy or tiredness when the timing of administration is unsuitable
• Possible increases in prolactin and cortisol, especially with GHRP-6
• Higher blood glucose; monitor levels if you have diabetes or prediabetes · Rare

Ipamorelin: not approved in the US.

• US

  Not approved

  FDA — no approval is established here; the regulatory category permits prescription compounding, with no 503A ban and telehealth availability.

  Rx required

  Yes

  503A

  Allowed

  Telehealth

  Available

1. Ipamorelin, a new growth hormone-releasing peptide (2001)

2. Growth hormone-releasing peptides: clinical applications (2008)

3. Ipamorelin, the first selective growth hormone secretagogue. (1998)

   PMID 9849822DOI 10.1530/eje.0.1390552

4. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. (2024)

   PMID 39043357DOI 10.1016/j.physbeh.2024.114644

5. Ipamorelin growth hormone studies on ClinicalTrials.gov (2024)